Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a fluid from stem cells ease knee pain without surgery?

NCT ID NCT07157891

Symptom relief Sponsor: University of the Punjab Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial tests whether injecting a fluid made from stem cells (called secretome) mixed with growth factors from the patient's own blood can safely reduce knee pain and improve function in people with mild knee osteoarthritis. The study will enroll 25 adults aged 30-55 with early-stage arthritis. Researchers will monitor pain, stiffness, and any side effects over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MSC-derived secretome (cell-free fluid from stem cells) combined with plasma rich in growth factors (PRGF) from the patient's own blood
What this could lead to
If it works, this could point toward a non-surgical, cell-free treatment to ease knee pain and improve function in early osteoarthritis.
What could go wrong
This is a very early, small trial (25 people) testing safety first. The treatment may not reduce pain or repair cartilage, and joint injections carry infection or irritation risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 25 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 55 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Following is the inclusion criteria for the enrolment of patients affected with damaged cartilage in this study: * Diagnosed with primary OA in one or both knees based on American College of Rheumatology criteria * Grade I and II Arthritis * Joint pain ≥ 20mm measured by visual analogue scale * Age ranges from 30-55 years of age * BMI 27.12 ± 4.38 * Patients with no previous surgical interventions to lower limb * Willing to participate in the study Exclusion Criteria: * • Secondary OA due to trauma, infection, rheumatoid arthritis, congenital disease or other inflammatory disorders of the knee * Diagnosed with a systemic autoimmune disorder, immunodeficiency or coagulation disorder * Had history of malignancy * History of allergy or allergic constitution * Pregnant or breastfeeding women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cartilage degeneration are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ankle injury Knee Injuries osteoarthritis osteoarthritis, knee

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cartilage degeneration Knee injury Osteoarthritis (OA)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.